January 5, 2010 – Intuity Medical, Inc., a privately-held company developing innovative technologies in diabetes management, announced that it has secured a $64M Series D financing round. The funds were contributed by new investors Venrock and Emergent Medical Partners; and existing investors Investor Growth Capital, Thomas, McNerney and Partners, U.S. Venture Partners, and Versant Ventures.
Intuity will utilize the proceeds for the U.S. commercialization and distribution of its All-in-One System, following regulatory clearance. All-in-One is the world’s first fully integrated blood glucose monitor, providing greater convenience, ease of use and discretion in glucose testing... [PDF]Intuity Medical's Press Release -
Blog Archive
-
▼
2010
(70)
-
▼
March
(11)
- Sanofi-aventis & AgaMatrix : worldwide agreement ...
- DARA BioSciences : Phase I Clinical Study of DB959...
- iCo Therapeutics : Phase 1 DME Clinical Trial Upda...
- MacuSight : Fast Track Designation from FDA for Pe...
- ThromboGenics : results from a Phase IIa trial eva...
- NephroGenex : Full Enrollment in New PYR 210Pyrido...
- Salix : FDA Marketing Approval for Metozolv™ ODT (...
- Intrinsic Bioprobes : discovery and exclusive lice...
- Intuity Medical : $64M Series D Financing
- Insulet and Ypsomed : International Distribution A...
- Dr. Reddy's and Rheoscience : headline results fro...
-
▼
March
(11)
Saturday, March 6, 2010
Intuity Medical : $64M Series D Financing
Libellés :
Blood Glucose Monitoring,
Intuity Medical